One limitation to the use of interferon inducers as antiviral chemotherapeutic agents is the production of toxic side effects in the host. In recent years there has been considerable interest in the development of nontoxic, lowmolecular-weight compounds that induce the production of interferon in vivo. A number of natural or synthetic compounds of this type, including 9-methylstreptimidone (12) , CP-20,961 (3), 10-carboxymethyl-9-acridanone (7) , quinacrine (2), MA-56 (15) , tilorone hydrochloride (8, 17) , 2-amino-5-bromo-6-methyl-4-pyrimidinol (U-25,166) (10) , and BL-20803 (14) , have been reported to induce interferon and have antiviral activity in a variety of experimental viral infections. Of particular interest are the compounds quinacrine, MA-56, tilorone, U-25,166, and BL-20803, which induce high levels of interferon after oral administration. BL-3849A, the structure ofwhich is shown in Fig. 1 , is a 7-methyl derivative of BL-20803 (14) . The purpose ofthis paper is to describe the interferon-inducing capacity of this compound and its antiviral activity in a number of experimental viral infections in mice.
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MATERIALS AND METHODS Animals. Adult (7 to 9 weeks old), female Swiss Webster mice and newborn (5 to 7 days old) mice were obtained from Simonsen Laboratories, Gilroy, Calif. They were housed under conditions of constant temperature and a 12-h light cycle, with food and water provided as needed.
Viruses. Rochester mouse virus (RMV) is a largeplaque variant of encephalomyocarditis (EMC) virus which will infect mice when administered by the intranasal route. The isolation and characterization of this virus has been described previously (16 Interferon induction and assay. BL-3849A was prepared by Bristol Laboratories, Syracuse, N.Y., and was provided to us through the Antiviral Substances Program, NIH. The drug was stored as a powder at room temperature until used. For oral or i.p. administration, the drug was dissolved in phosphate-buffered saline (PBS) at appropriate concentrations to give a volume of 0.1 ml/mouse. Oral administration of drug was accomplished by using an infant feeding tube (size, 5 French; Pharmaseal Laboratories, Glendale, Calif.) attached to a 1-ml syringe. Polyriboinosinic-polyribocytidylic acid [poly(I:C)] was prepared by P-L Laboratories, Milwaukee, Wis., and was provided to us through the Antiviral Substances Program, NIH. It was supplied as a solution at a concentration of 1 mg/ml and stored at -20°C until used. Tilorone hydrochloride was kindly furnished by G. D. Mayer, Merrell-National Laboratories, Cincinnati, Ohio, and was stored as a powder at 4°C until used. It was dissolved in PBS just before use and was administered orally with the infant feeding tube.
Interferon in mouse serum was assayed using confluent L-cell monolayer cultures in 35-mm plastic petri dishes. The plaque reduction assay, using vesicular stomatitis virus as the challenge virus, has been described previously (6, 17) . An internal laboratory reference interferon standard was included with each assay, and the sensitivity of our assay was compared with the interferon standard obtained from NIH. In our assay system, the NIH standard had a titer of approximately 5,000 units in comparison with its accepted titer of 6,500 units.
Statistical evaluation. To compare the final mortality of untreated and drug-treated mice, the data were evaluated by the Fisher exact test. To evaluate the differences in the mean day of death (MDD) between untreated and treated animals, the data were compared by the Mann-Whitney U test. A P value of <0.05 was considered to be significant.
RESULTS
Kinetics of interferon response induced by BL-3849A. The serum interferon response induced by BL-3849A in adult and newborn mice is illustrated in Fig. 2 . BL-3849A was administered to adult mice by either the oral (300 mg/ kg) or the i.p. route (100 mg/kg). Newborn mice were given BL-3849A by the i.p. route at a concentration of 100 mg/kg. At each of the indicated times after injection of the inducers, four mice were bled, and the serum was collected, pooled, and assayed for interferon. The results are plotted as a mean of two separate experiments. After i.p. administration to adult mice, a peak serum interferon titer of 3,000 units was observed at 18 h, with a gradual decline to undetectable levels by 36 h. The serum interferon levels were above 1,000 units between 9 and 18 h. After oral administration of BL-3849A to adult mice, a plateau in the interferon response of approximately 4,000 units was observed between 15 and 30 h. Detectable levels of interferon persisted until 48 h after administration of the inducer. Newborn mice exhibited a marked decrease in the interferon response after i.p. injection as compared with adult mice. A maximum titer of only 300 units occurred at about 18 h and gradually declined to undetectable levels at 36 h. The interferon response to oral administration of tilorone and to i.p. injection of poly(I:C) in adult mice was also examined (data not shown) and shown to be similar to that published previously (4a, 17) . Peak serum levels of 3,000 to 5,000 units were observed 6 to 9 h after injection of poly(I:C), and levels of 4,000 to 8,000 units were observed 18 to 24 h after tilorone administration.
Hyporeactivity to interferon induction. One potential limitation to the use of interferon inducers as chemotherapeutic agents is hyporeactivity or the progressive reduction in the magnitude of the interferon response that develops with multiple doses of the inducer (4a, 6, 17) . To determine if multiple injections of BL-3849A resulted in the development of a hyporeactive interferon response, groups of mice were inoculated with 300 mg/kg orally or 100 mg/kg i. Table 1 . After the initial injection of BL-3849A, 4,300 and 3,800 units of interferon were induced by oral and i.p. administration, respectively. After the second injection of the inducer, the interferon response was reduced to 10 to 20% of that with a single dose. After the fourth dose by either route, the serum interferon levels decreased to 3% of the response with a single injection.
Treatment of mice inoculated intranasally with RMV. Adult mice were infected by the intranasal route with 0.03 ml, containing 105 plaque-forming units, of RMV by applying the inoculum to the external nares through a 26-gauge needle. The animals exhibited ruffled fur and hunching by day 3 after inoculation, followed by paralysis and death on days 4 to 7. The pathogenesis of this experimental infection is illustrated in Fig. 3 . After intranasal inoculation, initial viral replication occurred in the lung. A viremia was first detected at 12 to 24 h after inoculation, with seeding of the heart and lungs by 36 h. Virus was first detectable in brain tissue at 48 h; replication to high titers was observed until the death of the mice. The results of treatment with BL-3849A on this experimental infection are summarized in Table  2 . The untreated control group of mice had a final mortality of 80%, with a MDD of 4.6 days. Animals that received BL-3849A orally either 18 h before or 1 h after RMV inoculation had a significant reduction in final mortality and an increased MDD. Initiation of treatment 24 h after viral inoculation failed to significantly alter final mortality or the MDD. Administration, i.p., of BL-3849A 18 h before RMV inoculation also significantly reduced final mortality. Treatment initiated i.p. 1 or 24 h after infection, however, was not effective.
Treatment of mice inoculated i.p. with EMC virus. To determine the effectiveness of treatment of BL-3849A on an EMC virus infection initiated systemically, adult mice were inoculated by the i.p. route with approximately 10 plaque-forming units of EMC virus. The pathogenesis of this model infection has been published previously (9) and is characterized by a viremia, followed by spread of virus to visceral target organs and to the brain. The animals exhibit fur ruffling and hunching on days 4 to 6, followed by paralysis and death on days 6 to 8. The effect of treatment on EMC virus infection of mice is shown in trol group that received PBS on the same schedule as the drug-treated groups had a final mortality of 80% and a MDD of 6.4 days. BL-3849A administered orally 18 h before infection was highly effective in reducing final mortality and increasing the MDD. Treatment initiated after infection was less effective. Similar results were observed with oral tilorone therapy. BL-3849A given by the i.p. route either 18 h before or 1 h after viral inoculation also significantly reduced final mortality. If treatment was initiated 24 h after infection, no effect on mortality was observed, but the MDD was significantly increased. Poly(I:C) treatment i.p. was more effective than BL-3849A in that therapy could be initiated as late as 24 h after infection and still significantly reduce mortality and increase the MDD groups of mice were also treated with tilorone orally or with poly(I:C) i.p. In the virus control group treated with PBS, the mice had a final mortality of93% and a MDD of 11.3 days. When BL-3849A was administered orally, only those mice that received the drug 18 h before infection had a reduced final mortality. A similar result was noted in the tilorone-treated mice. No significant effect was noted when BL-3849A was given by the i.p. route. In contrast, treatment with poly(I:C) by the i.p. route was very effective in reducing final mortality, even when therapy was initiated 24 h after infection. DISCUSSION BL-3849A is a new low-molecular-weight compound which induces high levels ofcirculating interferon after either oral or i.p. administration. The onset of the interferon response after oral treatment was delayed as compared Multiple injections of BL-3849A resulted in a marked hyporeactivity on the part ofthe host to produce interferon. This is not unusual in that every inducer we have tested has also resulted in hyporeactivity of interferon induction after the second or third injection (4a, 6, 11, 17) . Although there is evidence to suggest that the antiviral state induced by interferon production in vivo may persist in spite of decreasing levels of serum interferon (1, 13, 19) , this potential limitation to the use of interferon inducers and its relationship to antiviral effect need to be further investigated.
Oral treatment with BL-3849A of mice inocu- 10 to 15 h after viral challenge) was necessary to inhibit the development of viremia and subsequent seeding of target organs. This requirement for early induction of interferon for successful treatment of EMC virus infections with poly(I:C) or poly(I:C)-polyilysine has been described previously (11, 18) .
In no case was therapy effective if initiated 24 h after infection. The lack of efficacy at this time period appears to be due to the amount of time required for the induction of interferon by BL-3849A. By the time circulating interferon was detectable, viremia had already developed and target organs were being seeded. The reasons why i.p. therapy with BL-3849A was less successful than oral treatment in the infections with RMV, SFV, and H. hominis are not completely explained. It may be that the lower levels and shorter duration of the interferon response associated with the i.p. route of inoculation played a role.
BL-3849A is a new, relatively nontoxic interferon inducer that induces high levels of interferon in mice when administered by either the oral or ip. route and has antiviral activity against both ribonucleic acid and deoxyribonucleic acid viral infections of mice. When administered by the oral route the effectiveness was similar to that of tilorone, but when injected by the i.p. route it was less effective than poly(I:C). The possibility that BL-3849A will offer the advantages of an oral interferon inducer and also be less toxic suggests that further evaluation of this compound is warranted. It should be noted, however, that tilorone hydrochloride, another low-molecular-weight compound which also induces interferon by the oral route in mice, is not an effective inducer in humans (4) . This observation suggests that BL-3849A should be studied in other animal species, including primates and humans, before its full potential as an antiviral agent can be determined.
